Court upholds legal ruling on AstraZeneca 'Crestor' patent

On Friday December 14th, the Court of Appeals for the Federal Circuit announced that it had upheld the District Court in Delaware's finding that biopharmaceutical business AstraZeneca's substance patent protecting Crestor is valid and enforceable.

On Friday December 14th, the Court of Appeals for the Federal Circuit announced that it had upheld the District Court in Delaware's finding that biopharmaceutical business AstraZeneca's substance patent protecting Crestor is valid and enforceable.

The ruling follows legal wranglings dating back five years. In 2007, nine generic drug manufacturers filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications of non-infringement, invalidity, or unenforceability with respect to the Crestor '314 substance patent.

AstraZeneca and Shionogi, the owner of the '314 patent, filed patent infringement suits against eight manufacturers who had challenged the '314 substance patent. The suits were consolidated by order of the Judicial Panel on Multidistrict Litigation and tried in the U.S. District Court, District of Delaware.

In June 2010, the US District Court for the District of Delaware found the '314 patent valid and enforceable and infringed by the eight generic defendants.

Following last week's decision, the defendants may seek a rehearing and/or review by the U.S. Supreme Court.

AstraZeneca's share price was down 0.05% to 2,922.50p at 11:45 on Monday morning.

MF

Recommended

Improve your odds of investment success with these three stocks
Share tips

Improve your odds of investment success with these three stocks

Professional investor Tom Wildgoose of the Nomura Global High Conviction Fund highlights three of his favourite stocks.
2 Aug 2021
How to profit from pampered pets beyond the pandemic
Share tips

How to profit from pampered pets beyond the pandemic

Covid-19 has greatly boosted ownership. But the market had been expanding for years, and demographic, cultural and medical trends all point to long-te…
30 Jul 2021
Share tips of the week – 30 July
Share tips

Share tips of the week – 30 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Jul 2021
Robinhood is going public – should you invest?
US stockmarkets

Robinhood is going public – should you invest?

Online stockbroking app Robinhood is going public on the US stock exchange. Saloni Sardana looks at whether it's worth a punt.
29 Jul 2021

Most Popular

Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Cryptocurrency roundup: Twitter founder’s “DeFi” platform
Bitcoin & crypto

Cryptocurrency roundup: Twitter founder’s “DeFi” platform

In crypto this week: regulators are getting worried; Jack Dorsey’s bitcoin DeFi platform; and dogecoin’s co-founder lambasts cryptocurrencies.  Salon…
16 Jul 2021